Skip to main content

Table 4 Cox regression analysis for overall survival (OS), progression-free survival (PFS), and AML transformationa

From: The prognostic impact of mutations in spliceosomal genes for myelodysplastic syndrome patients without ring sideroblasts

 

OS

PFS

AML transformation

HR

95 % CI

P

HR

95 % CI

P

HR

95 % CI

P

Age (years)

1.029

0.987–1.073

0.174

1.039

0.996–1.084

0.074

1.007

0.952–1.064

0.819

Sex (male vs. female)

0.711

0.298–1.695

0.442

0.881

0.388–1.999

0.761

0.823

0.266–2.553

0.737

IPSS-R total score

1.634

1.263–2.115

<0.0001

1.546

1.214–1.969

<0.0001

1.699

1.200–2.405

0.003

SF3B1b (mut vs. WT)

2.663

0.572–12.397

0.212

1.533

0.193–12.145

0.686

   

U2AF1 (mut vs. WT)

1.648

0.365–7.436

0.516

4.840

1.655–14.157

0.004

1.252

0.149–10.494

0.836

SRSF2 (mut vs. WT)

1.216

0.270–5.485

0.799

4.379

1.604–11.952

0.004

2.672

0.697–10.245

0.152

  1. Statistical significance is indicated in boldface type
  2. aMultivariate analysis of OS, PFS, and AML transformation was performed using a Cox proportional hazards regression model that included age, sex, IPSS-R total score, and mutation status of SF3B1, U2AF1, and SRSF2
  3. bFor SF3B1mut patients, no AML transformation was seen
  4. AML, acute myeloid leukemia; CI, confidence interval; HR, hazard ratio; IPSS-R, revised International Prognostic Scoring System; mut, mutated; WT, wild-type